The aqueous extract of Solanum melongena inhibits PAR2 agonist-induced inflammation

Clin Chim Acta. 2003 Feb;328(1-2):39-44. doi: 10.1016/s0009-8981(02)00377-7.

Abstract

Background: Solanum melongena L. (Solanaceae) has antioxidant, analgesic, hypolipidemic and antiallergic activity.

Methods: The anti-inflammatory effects of the water extract of the S. melongena (SMWE) were investigated in PAR2-mediated mouse paw edema. Paw edema was induced by injection of trypsin or trans-cinnamoyl-LIGRLO-NH(2) (tc-NH(2)) into the hindpaw of mice. The SMWE (1, 5, 10, and 100 mg/kg) was orally administered 1 h before induction of inflammation.

Results: At doses of 5, 10, and 100 mg/kg, the SMWE showed significant inhibition of both paw edema and vascular permeability. The SMWE (10 mg/kg) significantly also inhibited PAR2 agonist-induced myeloperoxidase (MPO) activity and tumor necrosis factor (TNF)-alpha expression in paw tissue.

Conclusion: These results demonstrate that the SMWE inhibits PAR2 agonist-induced mouse paw edema.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Capillary Permeability / drug effects
  • Edema / prevention & control
  • Male
  • Mice
  • Mice, Inbred ICR
  • Oligopeptides / pharmacology
  • Peroxidase / antagonists & inhibitors
  • Plant Extracts / pharmacology*
  • Receptor, PAR-2
  • Receptors, Thrombin / agonists*
  • Solanum melongena*
  • Trypsin / pharmacology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Oligopeptides
  • Plant Extracts
  • Receptor, PAR-2
  • Receptors, Thrombin
  • Tumor Necrosis Factor-alpha
  • cinnamoyl-LIGRLO-amide
  • Peroxidase
  • Trypsin